212 related articles for article (PubMed ID: 17922561)
21. Buprenorphine may not be as safe as you think: a pediatric fatality from unintentional exposure.
Kim HK; Smiddy M; Hoffman RS; Nelson LS
Pediatrics; 2012 Dec; 130(6):e1700-3. PubMed ID: 23129079
[TBL] [Abstract][Full Text] [Related]
22. Opioid Overdose: Limitations in Naloxone Reversal of Respiratory Depression and Prevention of Cardiac Arrest.
van Lemmen M; Florian J; Li Z; van Velzen M; van Dorp E; Niesters M; Sarton E; Olofsen E; van der Schrier R; Strauss DG; Dahan A
Anesthesiology; 2023 Sep; 139(3):342-353. PubMed ID: 37402248
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic interactions between buprenorphine/naloxone and raltegravir in subjects receiving chronic buprenorphine/naloxone treatment.
Douglas Bruce R; Moody DE; Chodkowski D; Andrews L; Fang WB; Morrison J; Parsons TL; Friedland GH
Am J Drug Alcohol Abuse; 2013 Mar; 39(2):80-5. PubMed ID: 23421567
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics.
Yassen A; Olofsen E; Dahan A; Danhof M
J Pharmacol Exp Ther; 2005 Jun; 313(3):1136-49. PubMed ID: 15701707
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.
Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J
Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544
[TBL] [Abstract][Full Text] [Related]
26. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
Amato P
Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamics and arteriovenous difference of intravenous naloxone in healthy volunteers exposed to remifentanil.
Tylleskar I; Skulberg AK; Skarra S; Nilsen T; Dale O
Eur J Clin Pharmacol; 2018 Dec; 74(12):1547-1553. PubMed ID: 30143830
[TBL] [Abstract][Full Text] [Related]
28. Reversal of Opioid-Induced Respiratory Depression in Healthy Volunteers: Comparison of Intranasal Nalmefene and Intranasal Naloxone.
Ellison M; Hutton E; Webster L; Skolnick P
J Clin Pharmacol; 2024 Jul; 64(7):828-839. PubMed ID: 38436495
[TBL] [Abstract][Full Text] [Related]
29. Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects.
La Vincente SF; White JM; Somogyi AA; Bochner F; Chapleo CB
Clin Pharmacol Ther; 2008 Jan; 83(1):144-52. PubMed ID: 17568402
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic-pharmacodynamic relationships of cognitive and psychomotor effects of intravenous buprenorphine infusion in human volunteers.
Jensen ML; Sjøgren P; Upton RN; Foster DJ; Bonde P; Graae C; Skram U; Stevner L; Christrup LL
Basic Clin Pharmacol Toxicol; 2008 Jul; 103(1):94-101. PubMed ID: 18598301
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of respiratory depression induced by the combination of buprenorphine and diazepam in rats.
Vodovar D; Chevillard L; Caillé F; Risède P; Pottier G; Auvity S; Mégarbane B; Tournier N
Br J Anaesth; 2022 Mar; 128(3):584-595. PubMed ID: 34872716
[TBL] [Abstract][Full Text] [Related]
32. Is there enough naloxone to deter the diversion? Effect of concurrent administration of intravenous naloxone on opioid agonist effects of intravenous buprenorphine: A randomised, double-blind, within-subject, crossover study among opioid-dependent subjects.
Dhagudu NK; Ambekar A; Agrawal A; Rao R; Mishra AK; Jain R; Singh S
Drug Alcohol Rev; 2020 Jul; 39(5):595-603. PubMed ID: 32162420
[TBL] [Abstract][Full Text] [Related]
33. Does high-dose buprenorphine cause respiratory depression?: possible mechanisms and therapeutic consequences.
Mégarbane B; Hreiche R; Pirnay S; Marie N; Baud FJ
Toxicol Rev; 2006; 25(2):79-85. PubMed ID: 16958555
[TBL] [Abstract][Full Text] [Related]
34. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine.
Harris DS; Jones RT; Welm S; Upton RA; Lin E; Mendelson J
Drug Alcohol Depend; 2000 Dec; 61(1):85-94. PubMed ID: 11064186
[TBL] [Abstract][Full Text] [Related]
35. The pharmacokinetic and pharmacodynamic interactions between buprenorphine/naloxone and elvitegravir/cobicistat in subjects receiving chronic buprenorphine/naloxone treatment.
Bruce RD; Winkle P; Custodio JM; Wei LX; Rhee MS; Kearney BP; Ramanathan S; Friedland GH
J Acquir Immune Defic Syndr; 2013 Aug; 63(4):480-4. PubMed ID: 23599011
[TBL] [Abstract][Full Text] [Related]
36. Take-home naloxone treatment for opioid emergencies: a comparison of routes of administration and associated delivery systems.
Elzey MJ; Fudin J; Edwards ES
Expert Opin Drug Deliv; 2017 Sep; 14(9):1045-1058. PubMed ID: 27606669
[TBL] [Abstract][Full Text] [Related]
37. Tipranavir/ritonavir induction of buprenorphine glucuronide metabolism in HIV-negative subjects chronically receiving buprenorphine/naloxone.
Bruce RD; Moody DE; Fang WB; Chodkowski D; Andrews L; Friedland GH
Am J Drug Alcohol Abuse; 2011 Jul; 37(4):224-8. PubMed ID: 21438849
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of the combination tablet of buprenorphine and naloxone.
Chiang CN; Hawks RL
Drug Alcohol Depend; 2003 May; 70(2 Suppl):S39-47. PubMed ID: 12738349
[TBL] [Abstract][Full Text] [Related]
39. The diverse clinical uses of opioid receptor drugs.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2010 May; 48(5):11-4. PubMed ID: 20415289
[TBL] [Abstract][Full Text] [Related]
40. Clinical Pharmacokinetics and Pharmacodynamics of Naloxone.
Saari TI; Strang J; Dale O
Clin Pharmacokinet; 2024 Apr; 63(4):397-422. PubMed ID: 38485851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
